Deciding the best path forward to manufacture and commercialize cell and gene therapies means determining whether to partner with a CDMO or to build the development and manufacturing capacity in-house.
Explore Cytiva’s brand new single-use production facility in Wales, UK. This facility forms part of Cytiva’s >$1.5 billion investment in increased capacity to support the growing needs of the biopharmaceutical industry and to increase regional supply.
Explore the challenges imposed by deep cold storage conditions and outcomes on functional performance, sub-visible particles performance, and container closure integrity related to prefillable syringes.
A panel of experts discussed challenges and opportunities related to the development, clinical phases, and commercialization of biologics. They also offered insights on how to improve sponsor-CDMO relationships.